Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus ISORDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus ISORDIL.
GONITRO vs ISORDIL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing cGMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prevention of angina pectoris due to coronary artery diseaseAcute relief of angina episodesProphylaxis for angina before exertion or stress
Angina pectoris (prophylaxis and acute treatment)Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
None Documented
None Documented
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
60% bound, primarily to plasma albumin
~28% bound to albumin.
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (CrCl <30 mL/min) due to increased risk of hypotension and methemoglobinemia.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
["Hypotension (especially with volume depletion or alcohol)","Tolerance with prolonged use (intermittent dosing recommended)","Exacerbation of angina upon abrupt withdrawal","Use cautiously in hypertrophic cardiomyopathy"]
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
["Hypersensitivity to nitrates","Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)","Severe anemia","Increased intracranial pressure (head trauma, cerebral hemorrhage)","Acute circulatory failure (shock, vascular collapse)"]
Data Pending Review
Data Pending Review
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Category C
Category C
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.Sit or lie down when taking this medication to prevent dizziness or fainting.Avoid alcohol; it may worsen side effects like low blood pressure.Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.Store packets at room temperature away from moisture and heat. Do not open until ready to use.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.Avoid alcohol as it can increase the risk of hypotension and dizziness.Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.